Log In
Print
BCIQ
Print
Print this Print this
 

SAR650984

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionHumanized IgG1 mAb against CD38
Molecular Target CD38
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationHematologic malignancies
Indication DetailsTreat relapsed or refractory CD38+ hematological malignancies
Regulatory Designation

Partner

ImmunoGen Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today